Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ursula Anne Matulonis, M.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
An Analysis of Survivorship among Advanced Stage Ovarian Cancer Patients
Summer, 06/18/07 - 05/10/07

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 Feb 12. PMID: 30765148.
    Citations:    
  2. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Feb 07. PMID: 30753272.
    Citations:    
  3. Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA. POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. Gynecol Oncol Rep. 2019 May; 28:15-17. PMID: 30733993.
    Citations:    
  4. Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Leverson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 Mar; 18(3):642-655. PMID: 30679390.
    Citations:    Fields:    
  5. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA. Efficacy and safety of niraparib as maintenance treatment in older patients (=?70?years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 Mar; 152(3):560-567. PMID: 30638768.
    Citations:    Fields:    
  6. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 Jan 01; 5(1):e183773. PMID: 30347019.
    Citations:    Fields:    
  7. Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 Mar; 152(3):548-553. PMID: 30587441.
    Citations:    Fields:    
  8. Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 Dec 11; 25(11):2972-2980.e5. PMID: 30540933.
    Citations:    Fields:    
  9. Konstantinopoulos PA, Matulonis UA. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):997-1010. PMID: 30390770.
    Citations:    Fields:    
  10. Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, Qi J, Shapiro GI, Liu JF, Matulonis UA, Lin CY, Konstantinopoulos PA, Gray NS. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7. PMID: 30422115.
    Citations: 1     Fields:    
  11. Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2019 Mar 15; 25(6):1727-1736. PMID: 30413525.
    Citations:    Fields:    
  12. Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct; 119(9):1075-1085. PMID: 30353045.
    Citations:    Fields:    
  13. Matulonis UA. Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):xiii-xiv. PMID: 30390771.
    Citations:    Fields:    
  14. Stuver R, Petersen A, Guerrero-Garcia TA, Matulonis U, Richardson P, Singh P. Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. Case Rep Hematol. 2018; 2018:3029650. PMID: 30345126.
    Citations:    
  15. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 Nov; 8(11):1404-1421. PMID: 30213835.
    Citations:    Fields:    
  16. Najafov A, Zervantonakis IK, Mookhtiar AK, Greninger P, March RJ, Egan RK, Luu HS, Stover DG, Matulonis UA, Benes CH, Yuan J. BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biol. 2018 Aug; 16(8):e2005756. PMID: 30157175.
    Citations:    Fields:    
  17. Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018 Aug 13. PMID: 30107447.
    Citations:    Fields:    
  18. Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018 Aug 01; 29(8):1784-1792. PMID: 29767688.
    Citations: 1     Fields:    
  19. Merritt MA, Rice MS, Barnard ME, Hankinson SE, Matulonis UA, Poole EM, Tworoger SS. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol. 2018 Aug; 19(8):1107-1116. PMID: 30029888.
    Citations:    Fields:    
  20. Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug; 19(8):1117-1125. PMID: 30026000.
    Citations:    Fields:    
  21. Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. Gynecol Oncol. 2018 08; 150(2):219-226. PMID: 29937315.
    Citations:    Fields:    Translation:Humans
  22. Konstantinopoulos PA, Matulonis UA. PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clin Cancer Res. 2018 Sep 01; 24(17):4062-4065. PMID: 29871906.
    Citations: 1     Fields:    
  23. Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018 Jun; 16(6):426-437. PMID: 30067614.
    Citations:    Fields:    Translation:Humans
  24. Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2018 May 10. PMID: 29750700.
    Citations:    Fields:    
  25. Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Rep. 2018 Apr 03; 23(1):100-111. PMID: 29617652.
    Citations: 1     Fields:    
  26. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2018 02 07; 9(1):628. PMID: 29416025.
    Citations:    Fields:    
  27. Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220. PMID: 29397193.
    Citations: 1     Fields:    Translation:Humans
  28. Barroilhet L, Matulonis U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):585-590. PMID: 29366510.
    Citations: 1     Fields:    Translation:Humans
  29. Gunderson CC, Matulonis U, Moore KN. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):591-600. PMID: 29395304.
    Citations:    Fields:    Translation:Humans
  30. Tucker DW, Getchell CR, McCarthy ET, Ohman AW, Sasamoto N, Xu S, Ko JY, Gupta M, Shafrir A, Medina JE, Lee JJ, MacDonald LA, Malik A, Hasselblatt KT, Li W, Zhang H, Kaplan SJ, Murphy GF, Hirsch MS, Liu JF, Matulonis UA, Terry KL, Lian CG, Dinulescu DM. Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 Mar 15; 24(6):1389-1401. PMID: 29263182.
    Citations: 2     Fields:    
  31. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166. PMID: 29255160.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  32. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan; 14(2):123-136. PMID: 29098867.
    Citations: 1     Fields:    Translation:Humans
  33. Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57. PMID: 29122619.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  34. Zervantonakis IK, Iavarone C, Chen HY, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis U, Leverson JD, Sampath D, Mills GB, Brugge JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 08 28; 8(1):365. PMID: 28848242.
    Citations: 2     Fields:    Translation:Humans
  35. Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407. PMID: 28843653.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  36. Matulonis UA. Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 7(8):13-17. PMID: 28837127.
    Citations:    Fields:    
  37. Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. 2017 Jul 18; 8(29):47154-47160. PMID: 28454085.
    Citations: 3     Fields:    Translation:Humans
  38. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087. PMID: 28440955.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  39. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518. PMID: 27993796.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  40. Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017 03 01; 28(3):443-447. PMID: 28057663.
    Citations: 2     Fields:    Translation:Humans
  41. Mirza MR, Matulonis UA. Niraparib in Recurrent Ovarian Cancer. N Engl J Med. 2017 02 23; 376(8):801-2. PMID: 28225676.
    Citations: 2     Fields:    Translation:Humans
  42. Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clin Cancer Res. 2017 Aug 01; 23(15):4086-4094. PMID: 28223274.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  43. Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017 Apr; 9(4):253-267. PMID: 28491146.
    Citations: 5     
  44. Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2):e1277308. PMID: 28344892.
    Citations: 4     
  45. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118. PMID: 28029313.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  46. Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062. PMID: 27882345.
    Citations: 27     Fields:    Translation:Humans
  47. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863. PMID: 27601552.
    Citations: 10     Fields:    Translation:Humans
  48. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22; 115(11):1313-1320. PMID: 27824811.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  49. Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130. PMID: 27793850.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  50. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun C, O'Malley DM, Wright AA. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433. PMID: 27442965.
    Citations: 4     Fields:    Translation:Humans
  51. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 12 01; 375(22):2154-2164. PMID: 27717299.
    Citations: 104     Fields:    Translation:HumansCTClinical Trials
  52. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016 Dec 01; 22(23):5651-5660. PMID: 27678458.
    Citations: 25     Fields:    Translation:HumansCells
  53. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1579-1589. PMID: 27617661.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  54. Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, Gilbert HN, Ware JA, Zhu R, Lu S, Huw LY, Wang Y, Koeppen H, Spoerke JM, Lackner MR, Aghajanian CA. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016 Nov 15; 122(22):3519-3528. PMID: 27603005.
    Citations: 7     Fields:    
  55. Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63. PMID: 27587625.
    Citations: 28     Fields:    Translation:Humans
  56. Evans T, Matulonis U. Next-Generation Sequencing: Role in Gynecologic Cancers. J Natl Compr Canc Netw. 2016 09; 14(9):1165-73. PMID: 27587626.
    Citations: 1     Fields:    Translation:Humans
  57. Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273. PMID: 27573169.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  58. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 08 25; 2:16061. PMID: 27558151.
    Citations: 21     Fields:    Translation:HumansPHPublic Health
  59. Lee LJ, Howitt B, Catalano P, Tanaka C, Murphy R, Cimbak N, DeMaria R, Bu P, Crum C, Horowitz N, Matulonis U, Viswanathan AN. Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 08; 142(2):293-8. PMID: 27210818.
    Citations: 5     Fields:    Translation:HumansCells
  60. Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol. 2016 08; 29(8):893-903. PMID: 27150160.
    Citations: 2     Fields:    Translation:Humans
  61. Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29. PMID: 26984416.
    Citations: 6     Fields:    Translation:Humans
  62. Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M. Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 06; 141(3):405-409. PMID: 27049967.
    Citations: 3     Fields:    Translation:Humans
  63. Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016 Jun 15; 122(12):1844-52. PMID: 27062051.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  64. Coleman RL, Matulonis UA. Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1. PMID: 27016221.
    Citations: 1     Fields:    Translation:Humans
  65. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98. PMID: 26871470; PMCID: PMC4924663.
    Citations: 56     Fields:    Translation:HumansCells
  66. Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016; 25(5):597-611. PMID: 26899229.
    Citations: 3     Fields:    Translation:HumansAnimals
  67. Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 06; 27(6):1013-9. PMID: 26961146.
    Citations: 19     Fields:    Translation:Humans
  68. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504. PMID: 26895621.
    Citations: 5     Fields:    Translation:Humans
  69. Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016 Jan 26; 14(3):429-439. PMID: 26774475; PMCID: PMC4731274.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  70. Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, Campos SM, Matulonis UA, Castells MC. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12. PMID: 26725998.
    Citations: 3     Fields:    Translation:Humans
  71. Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075. PMID: 27141347.
    Citations: 10     
  72. Liu J, Konstantinopoulos PA, Matulonis UA. Genomic testing and precision medicine--What does this mean for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):3-5. PMID: 26657840.
    Citations: 1     Fields:    Translation:Humans
  73. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23. PMID: 26181000.
    Citations: 68     Fields:    Translation:HumansCells
  74. Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7. PMID: 26240233; PMCID: PMC4554746.
    Citations: 25     Fields:    Translation:Humans
  75. Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23. PMID: 26119093.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  76. Liu JF, Matulonis UA. Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8. PMID: 26115795.
    Citations: 2     Fields:    Translation:Humans
  77. Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochem Biophys Res Commun. 2015 Aug 07; 463(4):551-6. PMID: 26047697.
    Citations: 19     Fields:    Translation:Animals
  78. Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol. 2015; 5:123. PMID: 26082895.
    Citations: 3     
  79. Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63. PMID: 25847373; PMCID: PMC4685031.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  80. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989. PMID: 25723171.
    Citations: 64     Fields:    Translation:HumansCells
  81. Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015 Feb 15; 75(4):628-34. PMID: 25634215.
    Citations: 17     Fields:    Translation:HumansCells
  82. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18. PMID: 25524310.
    Citations: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
  83. Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53. PMID: 25528496.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  84. Matulonis UA, Oza AM, Ho TW, Ledermann JA. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. 2015 Jun 01; 121(11):1737-46. PMID: 25336142.
    Citations: 6     Fields:    Translation:Humans
  85. Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014 Oct 15; 20(20):5150-6. PMID: 25320365.
    Citations: 27     Fields:    Translation:HumansAnimals
  86. Konstantinopoulos PA, Matulonis UA. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer. 2015 Feb 01; 121(3):331-4. PMID: 25224324.
    Citations: 4     Fields:    Translation:Humans
  87. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14. PMID: 25218906.
    Citations: 82     Fields:    Translation:HumansCTClinical Trials
  88. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85. PMID: 25016924.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  89. Barry WT, Birrer MJ, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA5500. PMID: 28141978.
    Citations:    
  90. Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. ß-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol. 2014 Aug; 134(2):426-7. PMID: 24952365.
    Citations: 4     Fields:    Translation:Humans
  91. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul; 15(8):852-61. PMID: 24882434.
    Citations: 219     Fields:    Translation:HumansCTClinical Trials
  92. Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014 May 15; 5(9):2678-87. PMID: 24798692.
    Citations: 11     Fields:    Translation:HumansCells
  93. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014 Jun; 124(6):2611-25. PMID: 24762435; PMCID: PMC4038562.
    Citations: 34     Fields:    Translation:HumansCells
  94. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9. PMID: 24607283.
    Citations: 24     Fields:    Translation:HumansCells
  95. Picard M, Matulonis UA, Castells M. Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):389-402. PMID: 24616544.
    Citations: 1     Fields:    Translation:Humans
  96. Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol. 2013 Dec 11; 3:296. PMID: 24377084; PMCID: PMC3858677.
    Citations: 13     
  97. Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013; 8(11):e80023. PMID: 24265793; PMCID: PMC3827141.
    Citations: 31     Fields:    Translation:Humans
  98. Lee LJ, Demaria R, Berkowitz R, Matulonis U, Viswanathan AN. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014 Jan; 132(1):65-9. PMID: 24211401.
    Citations: 3     Fields:    Translation:Humans
  99. Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60. PMID: 24201015.
    Citations: 6     Fields:    Translation:Humans
  100. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1199-209. PMID: 24142821.
    Citations: 30     Fields:    Translation:Humans
  101. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83. PMID: 24037752; PMCID: PMC3972000.
    Citations: 51     Fields:    Translation:Humans
  102. Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6. PMID: 23954902.
    Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
  103. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 01; 19(19):5485-93. PMID: 23922302.
    Citations: 25     Fields:    Translation:Humans
  104. Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL. Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013 Jul-Aug; 36(4):256-64. PMID: 23086133.
    Citations: 5     Fields:    Translation:Humans
  105. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. PMID: 23810467.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  106. Townamchai K, Berkowitz R, Bhagwat M, Damato AL, Friesen S, Lee LJ, Matulonis U, O'Farrell D, Viswanathan AN. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2013 Apr; 129(1):18-21. PMID: 23262378.
    Citations: 7     Fields:    Translation:Humans
  107. Lu W, Matulonis UA, Dunn JE, Lee H, Doherty-Gilman A, Dean-Clower E, Goodman A, Davis RB, Buring J, Wayne P, Rosenthal DS, Penson RT. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 Dec; 24(4):233-240. PMID: 24761165.
    Citations: 1     
  108. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1339-49. PMID: 23138163.
    Citations: 19     Fields:    Translation:Humans
  109. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):E2939-48. PMID: 23019585; PMCID: PMC3491453.
    Citations: 95     Fields:    Translation:HumansAnimalsCells
  110. Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31. PMID: 22921155.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  111. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012 Oct 15; 18(20):5806-15. PMID: 22912389; PMCID: PMC4205235.
    Citations: 41     Fields:    Translation:Humans
  112. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20. PMID: 22885865.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  113. Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012 Oct; 127(1):63-9. PMID: 22772063.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  114. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6. PMID: 22750258.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  115. Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):628-53. PMID: 22570293.
    Citations: 23     Fields:    Translation:Humans
  116. Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6. PMID: 22487536.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  117. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12; 366(15):1382-92. PMID: 22452356.
    Citations: 275     Fields:    Translation:HumansCTClinical Trials
  118. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1. PMID: 22366591.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  119. Godinez-Puig V, Frangos J, Hollmann TJ, Dryden-Peterson S, Matulonis U, Lipworth AD. Photo quiz. Rash in a patient with ovarian cancer. Clin Infect Dis. 2012 Feb 15; 54(4):538, 575-6. PMID: 22294566.
    Citations:    Fields:    Translation:Humans
  120. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, Quackenbush J, Matulonis UA. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012; 7(2):e30269. PMID: 22348002; PMCID: PMC3278409.
    Citations: 33     Fields:    Translation:HumansCells
  121. Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6. PMID: 22333992.
    Citations: 10     Fields:    Translation:Humans
  122. Horowitz N, Matulonis UA. New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56. PMID: 22244666.
    Citations:    Fields:    Translation:HumansCells
  123. Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401. PMID: 22747104.
    Citations: 2     Fields: